AS-601811

AS-601811 is a 5α-reductase inhibitor of type 1 of the enzyme which was under development for the treatment of acne, benign prostatic hyperplasia, hirsutism, male-pattern baldness, and prostate cancer but was never marketed.^[1][2] It is taken orally.^[1] The drug reached phase 1 clinical trials prior to the discontinuation of its development.^[1] It was being developed by Merck Serono.^[1][2]

AS-601811

Clinical data
Other names	AS-601811; AS601811
Routes of administration	Oral[1]
Drug class	5α-Reductase inhibitor
ATC code	None
Identifiers
IUPAC name 4,8-dimethyl-1,2,5,6-tetrahydrobenzo[f]quinolizin-3-one
CAS Number	194979-95-8
PubChem CID	10220187
UNII	LIV8A6AE5F
ChEMBL	ChEMBL118319
Chemical and physical data
Formula	C15H17NO
Molar mass	227.307 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC2=C(C=C1)N3CCC(=O)C(=C3CC2)C
InChI InChI=1S/C15H17NO/c1-10-3-5-14-12(9-10)4-6-13-11(2)15(17)7-8-16(13)14/h3,5,9H,4,6-8H2,1-2H3 Key:SNEPAAKJPPNOQM-UHFFFAOYSA-N

See also

• List of investigational hair loss drugs
• Epristeride
• MK-434